{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:36:54Z","timestamp":1777419414772,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To present the chemistry, pharmacology, and pharmacokinetics of parathyroid hormone (PTH) (1-84%) and review the available clinical trials that evaluate its efficacy and safety; clinical applicability of this agent and its relationship to other Food and Drug Administration (FDA)\u2013approved medications for treatment of osteoporosis are also discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>A MEDLINE search (1996\u2013December 2004%) was completed, along with a review of information obtained from the manufacturer, NPS Pharmaceuticals. Key search terms included parathyroid hormone, PTH (1\u201384%), and ALX 111.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION:<\/jats:title>\n                    <jats:p>Studies were selected based on their relevance and availability. Pertinent information, including objectives, design, demographics, outcomes, adverse events, dosing strategies, and therapeutic controversies, was extracted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>PTH (1-84%) is being developed for treatment of osteoporosis. Recent studies have shown that, when administered intermittently as a subcutaneous injection, PTH (1-84%) produces an increase in bone mineral density and prevents vertebral fractures. The fact that this agent contains the C-terminal region of PTH may differentiate it from PTH (1-34%), teriparatide, which is approved by the FDA for treatment of osteoporosis. Further trials are necessary to determine the role of PTH (1-84%) in combination with other treatments for osteoporosis and\/or the order in which PTH (1-84%) is given with these other agents. There are currently no comparative trials with other osteoporosis treatment modalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>PTH (1-84%), when given intermittently as a subcutaneous injection, appears to be a safe and efficacious treatment option for osteoporosis. Further trials are needed to determine its specific place in therapy compared with other treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1g146","type":"journal-article","created":{"date-parts":[[2005,8,2]],"date-time":"2005-08-02T22:44:08Z","timestamp":1123022648000},"page":"1511-1516","source":"Crossref","is-referenced-by-count":21,"title":["Parathyroid Hormone (1\u201384) and Treatment of Osteoporosis"],"prefix":"10.1177","volume":"39","author":[{"given":"Sarah P","family":"Shrader","sequence":"first","affiliation":[{"name":"Sarah P Shrader PharmD, Family Medicine Pharmacy Resident, South Carolina College of Pharmacy, Charleston, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly R","family":"Ragucci","sequence":"additional","affiliation":[{"name":"Kelly R Ragucci PharmD BCPS CDE, Associate Professor, Pharmacy and Clinical Sciences\/Family Medicine; Pharmacy Residency Program Director, Family Medicine, South Carolina College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,9,1]]},"reference":[{"key":"bibr1-aph.1G146","unstructured":"www.nof.org. National Osteoporosis Foundation (accessed 2005 Jan 22)."},{"key":"bibr2-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)69644-9"},{"key":"bibr3-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1210\/endo-16-5-547"},{"key":"bibr4-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1210\/endo-129-1-421"},{"key":"bibr5-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1210\/endo.132.4.8462456"},{"key":"bibr6-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1007\/BF01621907"},{"key":"bibr7-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)02342-8"},{"key":"bibr8-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.12.1067"},{"key":"bibr9-aph.1G146","first-page":"620","volume":"82","author":"Hodsman AB","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"bibr10-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3914"},{"key":"bibr11-aph.1G146","volume-title":"Package insert. Forteo (teriparatide)","year":"2004"},{"key":"bibr12-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1210\/endo-117-4-1632"},{"key":"bibr13-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.2.7955"},{"key":"bibr14-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6610"},{"key":"bibr15-aph.1G146","first-page":"115","volume":"21","author":"Manolagas SC","year":"2000","journal-title":"Endocr Rev"},{"key":"bibr16-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-73-6-1345"},{"key":"bibr17-aph.1G146","first-page":"525","volume":"50","author":"Groen EWJ","year":"1995","journal-title":"Therapie"},{"key":"bibr18-aph.1G146","volume-title":"PTH (1-84) prevents first vertebral fracture in postmenopausal women with osteoporosis: the TOP study (abstract)","author":"Ettinger M","year":"2004"},{"key":"bibr19-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031975"},{"key":"bibr20-aph.1G146","unstructured":"www.npsp.com\/news\/releasetxt.php?ReqId=648381. NPS Pharmaceuticals (accessed 2005 Jan 5)."},{"key":"bibr21-aph.1G146","volume-title":"The effects of PTH, alendronate alone or in combination on bone mass and turnover: 24 month results of the PaTH trial (abstract)","author":"Black DM","year":"2004"},{"key":"bibr22-aph.1G146","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.70.7.585"},{"key":"bibr23-aph.1G146","doi-asserted-by":"publisher","DOI":"10.4158\/EP.9.6.544"},{"key":"bibr24-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.3.320"},{"key":"bibr25-aph.1G146","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400100100017"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1G146","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:10:45Z","timestamp":1777374645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1G146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1345\/aph.1G146"],"URL":"https:\/\/doi.org\/10.1345\/aph.1g146","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}